Vertex Pharmaceuticals Inc. closed 10.71% below its 52-week high of $519.88, which the company reached on November 8th.

Vertex Pharmaceuticals Inc. closed 10.89% short of its 52-week high of $519.88, which the company achieved on November 8th.

About Vertex Pharmaceuticals Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases.

Vertex Pharmaceuticals (VRTX) reached $452.16 at the closing of the latest trading day, reflecting a +1.56% change compared to its last close.

Vertex also benefited from continued growth in its cystic fibrosis business." Is Vertex Pharmaceuticals Incorporated (VRTX) the Best Stock to Buy According to Jim Simons’ Renaissance Technologies?

Valued at a market cap of $117.7 billion, Vertex Pharmaceuticals Incorporated (VRTX) is a biotechnology company that ...

Vertex Pharmaceuticals VRTX has outperformed the market over the past 10 years by 1.82% on an annualized basis producing an average annual return of 13.32%. Currently, Vertex Pharmaceuticals has a ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the best biotech stocks to invest in now.

Review Vertex Pharmaceuticals Inc (VRTX:XNAS) stock and the current sustainability and ESG risk rating to help with your investing decisions.

Review which funds and institutions currently hold Vertex Pharmaceuticals Inc (VRTX:XNAS) stock for ownership information.

Vertex Pharmaceuticals (VRTX) on Tuesday announced that the European Commission has granted approval for Alyftrek for the treatment of people with cystic fibrosis.

Unlike traditional video tools that require separate audio work, the Veo 3 API generates videos with natural, perfectly-timed sound. Dialogue, ambient noise, and even subtle audio cues are built ...